SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 4 — Sick Visit — Flannery O'Connor

PatientFlannery O'Connor
Date of birth2001-03-25
IdentifiersMRN HR-ML046-SYN; SSN (made up) 000-46-1853
Document date2026-06-15
AuthorAugusta Pemberton-Diallo, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Burning on passing urine and going often for two days. [S]

History of Present Illness

Ms. O'Connor is a 25-year-old writer with systemic lupus erythematosus and class III lupus nephritis, seven weeks into treatment with mycophenolate 1000 mg twice daily, weekly belimumab, hydroxychloroquine, losartan, and prednisone, now 15 mg a day. For two days she has had burning on passing urine, frequency, urgency, and lower abdominal discomfort. She has no fever on her home thermometer, chills, back or flank pain, vomiting, vaginal discharge, or rash, and her joints are quiet. She has a levonorgestrel intrauterine system. She called because she had been told that any infection on her treatment should be seen the same day, and she wanted to know whether this was her kidneys. [S]

ElementDetail
OnsetTwo days ago
LocationBladder; no flank pain
DurationTwo days
CharacterBurning, frequency, urgency
SeverityModerate; writing still
ContextMycophenolate, belimumab, and prednisone 15 mg; intrauterine system
Modifying factorsExtra fluids help a little
Associated signs and symptomsNo fever, chills, flank pain, vomiting, or discharge

Review of Systems

SystemResultFinding
ConstitutionalNegativeNo fever or chills
GenitourinaryPositiveDysuria, frequency, urgency, suprapubic discomfort; no flank pain or discharge
GastrointestinalNegativeNo vomiting or diarrhea
MusculoskeletalNegativeNo joint pain or swelling
IntegumentaryNegativeNo rash

5 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Acetaminophen 500 mg oral tablet, two tablets (1000 mg) by mouth up to three times a day as needed for joint pain, no more than 3000 mg a dayTwo tablets up to every 8 hours as neededOral route2026-04-13activeS
Hydroxychloroquine sulfate 300 mg oral tablet, one tablet by mouth once daily (5 mg/kg of actual body weight), long termOne tablet once dailyOral route2026-04-22activeS
Losartan potassium 25 mg oral tablet, one tablet by mouth once daily, for proteinuria and blood pressureOne tablet once dailyOral route2026-04-22activeS
Methylprednisolone 500 mg intravenous infusion once daily for three daysOne infusion daily for three daysIntravenous route2026-04-29 to 2026-05-01completedS
Prednisone 5 mg oral tablet: 30 mg (six tablets) once daily from the day after the last pulse, reduced by 5 mg every two weeks to 10 mg, then to 5 mg a day or less by six monthsOnce daily, taperingOral route2026-04-29activeS
Mycophenolate mofetil 500 mg oral tablet, one tablet twice daily for one week, then two tablets (1000 mg) twice dailyTwo tablets twice dailyOral route2026-04-29activeS
Belimumab 200 mg/mL subcutaneous autoinjector: 400 mg (two injections) once weekly for four doses, then 200 mg once weeklyOnce weekly by self-injectionSubcutaneous route2026-04-29activeS
Cholecalciferol (vitamin D3) 1000 units oral tablet, one tablet by mouth once dailyOne tablet once dailyOral route2026-04-29activeS
Nitrofurantoin (monohydrate/macrocrystals) 100 mg oral capsule, one capsule by mouth twice daily with food for seven daysOne capsule twice daily for seven daysOral route2026-06-15 to 2026-06-21completedS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
2026-06-15Body height168cmS
2026-06-15Body weight62.4kgS
2026-06-15Body mass index (BMI) [Ratio]22.1kg/m2S
2026-06-15Systolic blood pressure124mm[Hg]S
2026-06-15Diastolic blood pressure78mm[Hg]S
2026-06-15Heart rate84/minS
2026-06-15Respiratory rate14/minS
2026-06-15Body temperature37.3CelS
2026-06-15Oxygen saturation in Arterial blood by Pulse oximetry99%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-06-15Leukocytes [#/volume] in Blood by Automated count7.910*3/uL4-11 10*3/uLNormalS
2026-06-15Creatinine [Mass/volume] in Serum or Plasma0.8mg/dL0.5-1.1 mg/dLNormalS
2026-06-15Potassium [Moles/volume] in Serum or Plasma4.6mmol/L3.5-5.1 mmol/LNormalS

Physical Exam

Vital signs recorded on 2026-06-15; see the Vital Signs section. [S]

SystemFinding
GeneralWell-appearing; temperature 37.3 °C, pulse 84/min
AbdomenMild suprapubic tenderness; no masses
BackNo costovertebral angle tenderness
SkinNo malar rash; no lesions
MusculoskeletalNo joint swelling or tenderness

Problems

ProblemClinical statusVerificationCodeProvenance
Pain and swelling of the small joints of both hands, the wrists, and the knees for three months, with an hour of morning stiffness, evening fevers to 38 °C, fatigue, and a red rash over the cheeks and nose after sun; told elsewhere it might be rheumatoid arthritis; cause to be establishedresolvedconfirmed M25.50S — Synthetic presenting concern at the index visit, superseded by the diagnosis of systemic lupus erythematosus at the second visit; joint pain in 1950 with suspected rheumatoid arthritis is documented (D).
Protein and blood in the urine: protein-to-creatinine ratio 1.6 g/g and 18 red cells per high-power field, with normal creatinine; cause to be establishedresolvedconfirmed R80.9S — Synthetic presenting finding at the index visit, superseded by the kidney biopsy diagnosis at the third visit.
Systemic lupus erythematosus, classified by the EULAR/ACR criteria (ANA 1:640 homogeneous; score 32 before the biopsy): inflammatory arthritis, acute cutaneous lupus (malar rash), fever, leukopenia with lymphopenia, mild thrombocytopenia, low C3 and C4, anti-dsDNA and anti-Sm positive; antiphospholipid antibodies and lupus anticoagulant negativeactiveconfirmed M32.19S — Synthetic modern diagnosis and results; her systemic lupus erythematosus, diagnosed in Atlanta in late 1950 or early 1951, is documented (D), but no finding from her lifetime is used.
Lupus nephritis, ISN/RPS class III (A), focal proliferative, on kidney biopsy: endocapillary proliferation in 9 of 30 glomeruli, activity index 6 of 24, chronicity index 1 of 12, full-house immunofluorescence; no thrombotic microangiopathy; urine protein-to-creatinine ratio 1.8 g/g; normal kidney functionactiveconfirmed M32.14S — Synthetic biopsy result and class; kidney involvement is documented at the end of her life, but no kidney finding from her lifetime is used.
Long-term glucocorticoid treatment for lupus nephritis, tapering to 5 mg a day or lessactiveconfirmed Z79.52S — Synthetic treatment status; the documented steroid harm in her life is the reason the episode keeps glucocorticoids low.
Long-term mycophenolate mofetil, with belimumab, for lupus nephritis; bone and infection protection in placeactiveconfirmed Z79.624S — Synthetic treatment status.
Levonorgestrel intrauterine system for highly effective contraception during mycophenolate treatmentactiveconfirmed Z97.5S — Synthetic contraception, chosen by the patient.
Acute cystitis on mycophenolate, belimumab, and prednisone 15 mg: two days of burning, frequency, and urgency without fever or flank pain; urine culture grew Escherichia coli sensitive to nitrofurantoin; resolved with seven days of nitrofurantoinresolvedconfirmed N30.00S — Synthetic common infection in an immunosuppressed young woman; coded without hematuria because the persistent hematuria is from her nephritis.

Assessment and Plan

Guideline basis: EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann Rheum Dis 2024;83(1):15-29 (2023); 2024 American College of Rheumatology (ACR) Guideline for the Screening, Treatment, and Management of Lupus Nephritis. Arthritis Rheumatol 2025;77(9):1115-1135 (2024); International Clinical Practice Guidelines for the Treatment of Acute Uncomplicated Cystitis and Pyelonephritis in Women: A 2010 Update by the IDSA and ESCMID. Clin Infect Dis 2011;52(5):e103-e120 (2010)

Follow-up: Culture result by telephone in two days. Rheumatology blood count as scheduled. Three-month review in six weeks. Next scheduled visit 2026-07-27: three-month response assessment for lupus nephritis and glucocorticoid taper. [S]